Resverlogix

TSX:RVX

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Investing News NetworkYour trusted source for investing success

Leigh Goehring: Gold's "Massive Bull Market" Just Starting; Uranium and Copper Outlook

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Top 4 Largest Lithium Reserves by Country (Updated 2024)

How Could Trump's US Election Win Affect the Gold Price?

McDermitt PFS Demonstrates Multi-Decade Competitive Source of US Lithium Carbonate

OSISKO METALS EXPANDS LEADERSHIP TEAM AND ANNOUNCES C$100 MILLION BOUGHT DEAL FINANCING

Silver47 Drills 2.48m of 14.95 g/t Gold, 249.50 g/t Silver, 21.97% Zinc, 7.03% Lead, 0.42% Copper at Its Red Mountain Project, Alaska

Osisko Metals Announces Significant Increase in Mineral Resources at Gaspé Copper

SAGA Metals Announces Assay Results from North Wind Iron Ore Project

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Silver47 Exploration

Purpose Bitcoin ETF

Jindalee Lithium

Syntheia

2024 Gold Outlook Report

2024 Lithium Market Outlook

2024 AI Market Outlook Report

Silver Price Forecast - What Happened And Where Do We Go From Here?

Resverlogix

Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases

Resverlogix Announces $26 Million Private Placement

Resverlogix Intends to Pursue U.S. Listing

Interactive Chart